Boothbay Fund Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Boothbay Fund Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-682	Closed	-$327K	–	1889
2020 Q4	$327K	Buy	+682	New	+$3.45K	0.01%	919
2020 Q1	–	Sell	-863	Closed	-$899K	–	1147
2019 Q4	$899K	Buy	+863	New	+$6.28K	0.08%	340
2018 Q3	–	Sell	-65	Closed	-$296K	–	984
2018 Q2	$296K	Hold	65	–	–	0.03%	481
2018 Q1	$343K	Sell	65 -178	-73%	-$10.4K	0.04%	425
2017 Q4	$1.65M	Buy	243 +179	+280%	+$12.5K	0.24%	80
2017 Q3	$527K	Sell	64 -23,336	-100%	-$1.85M	0.09%	249
2017 Q2	$2.19M	Buy	23,400 +10,600	+83%	+$649K	0.46%	40
2017 Q1	$815K	Buy	12,800 +6,900	+117%	+$419K	0.15%	172
2016 Q4	$262	Buy	+5,900	New	+$208K	0.06%	466

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Boothbay Fund Management's CLVS Position: Q4 2022 in Review

Boothbay Fund Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 36,350 shares — an estimated $43K sold.

Boothbay Fund Management first reported a position in CLVS in Q2 2017 and held it in 13 quarters. The position peaked at $1.24M in Q1 2019. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Boothbay Fund Management reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Boothbay Fund Management sold 36,350 Clovis Oncology, Inc. shares in Q4 2022, an estimated $43K.
Boothbay Fund Management first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 13 quarters.
Boothbay Fund Management's Clovis Oncology, Inc. position peaked at $1.24M in Q1 2019.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.